id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0626-0007,FDA,FDA-2016-E-0626,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-19T04:00:00Z,2017,9,2017-09-19T04:00:00Z,,2017-09-19T13:45:19Z,,0,0,0900006482b4d8ae
FDA-2016-E-0626-0006,FDA,FDA-2016-E-0626,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: COSENTYX,Notice,Determinations,2016-12-20T05:00:00Z,2016,12,2016-12-20T05:00:00Z,2017-06-20T03:59:59Z,2016-12-20T14:49:29Z,2016-30528,0,0,09000064824290f2
FDA-2016-E-0626-0005,FDA,FDA-2016-E-0626,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-08T05:00:00Z,2016,12,2016-12-08T05:00:00Z,,2016-12-08T19:21:08Z,,0,0,09000064823ee910
FDA-2016-E-0626-0004,FDA,FDA-2016-E-0626,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:36:00Z,,0,0,09000064822ea233
FDA-2016-E-0626-0003,FDA,FDA-2016-E-0626,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-02T04:00:00Z,2016,5,2016-05-02T04:00:00Z,,2016-05-02T21:54:28Z,,0,0,0900006481fa1bbb
FDA-2016-E-0626-0001,FDA,FDA-2016-E-0626,Patent Extension Application from Novartis Pharmaceutical Corp. (on behalf of Novartis AG),Other,Application,2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T21:30:32Z,,0,0,0900006481e78c71
FDA-2016-E-0626-0002,FDA,FDA-2016-E-0626,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T21:30:40Z,,0,0,0900006481e79123